Mechanistically, IL-6 promotes endothelial dysfunction, smooth-muscle proliferation, and thrombogenic remodeling through JAK/STAT3 signaling [36], all of which contribute to plaque instability and restenosis after CEA. The gene discussed is STAT3; the disease is endothelial dysfunction.